G. Chen

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 468 citations

Medicine, Oncology, Pharmacology +14

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 120 citations · Full text

Medicine, Oncology, Pharmacology +14

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Ying Cheng, Q. Wang, K. Li et al. · Journal of Thoracic Oncology · 2018 · 59 citations · Full text

Medicine, Oncology, Pharmacology +9

CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

Qing Zhou, Yi‐Long Wu, Ying Cheng et al. · Annals of Oncology · 2019 · 55 citations

Medicine, Oncology, Pharmacology +15

Stroke Volume Variation for Prediction of Fluid Responsiveness in Patients Undergoing Gastrointestinal Surgery

Cheng Li, Fuqing Lin, Shukun Fu et al. · International Journal of Medical Sciences · 2013 · 39 citations · Full text

Medicine, Perioperative Medicine, Surgery +16